New drug duo aims to fight rare melanoma before surgery

NCT ID NCT07517653

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests two drugs—SHR-1701 (an immunotherapy) and famitinib (which cuts off tumor blood supply)—given before surgery for resectable mucosal melanoma, a rare and aggressive skin cancer. After surgery, treatment is tailored based on how well the tumor responded. The study will enroll 70 adults to see if this approach improves event-free survival and overall outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1701 (an immunotherapy drug) and famitinib (a drug that blocks blood vessel growth)
What this could lead to: If successful, this combination could become a new standard treatment before and after surgery for mucosal melanoma, potentially improving survival and reducing recurrence.
What could go wrong: This is an early phase II trial with only 70 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma mucosal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.